GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:ATYR) » Definitions » Cyclically Adjusted FCF per Share

ATYR (aTyr Pharma) Cyclically Adjusted FCF per Share : $-13.76 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is aTyr Pharma Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

aTyr Pharma's adjusted free cash flow per share for the three months ended in Mar. 2025 was $-0.178. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-13.76 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-06-26), aTyr Pharma's current stock price is $5.31. aTyr Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was $-13.76. aTyr Pharma's Cyclically Adjusted Price-to-FCF of today is .


aTyr Pharma Cyclically Adjusted FCF per Share Historical Data

The historical data trend for aTyr Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

aTyr Pharma Cyclically Adjusted FCF per Share Chart

aTyr Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -17.76 -14.10

aTyr Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.91 -16.14 -15.15 -14.10 -13.76

Competitive Comparison of aTyr Pharma's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, aTyr Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Cyclically Adjusted Price-to-FCF falls into.


;
;

aTyr Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, aTyr Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.178/134.9266*134.9266
=-0.178

Current CPI (Mar. 2025) = 134.9266.

aTyr Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -10.572 100.684 -14.168
201509 -5.849 100.392 -7.861
201512 -5.883 99.792 -7.954
201603 -7.586 100.470 -10.188
201606 -8.376 101.688 -11.114
201609 -8.713 101.861 -11.541
201612 -6.931 101.863 -9.181
201703 -8.343 102.862 -10.944
201706 -5.717 103.349 -7.464
201709 -5.062 104.136 -6.559
201712 -4.895 104.011 -6.350
201803 -5.204 105.290 -6.669
201806 -4.329 106.317 -5.494
201809 -3.043 106.507 -3.855
201812 -2.235 105.998 -2.845
201903 -2.494 107.251 -3.138
201906 -1.486 108.070 -1.855
201909 -1.113 108.329 -1.386
201912 -1.272 108.420 -1.583
202003 0.275 108.902 0.341
202006 -0.686 108.767 -0.851
202009 -0.577 109.815 -0.709
202012 -0.503 109.897 -0.618
202103 -0.414 111.754 -0.500
202106 -0.483 114.631 -0.569
202109 -0.635 115.734 -0.740
202112 -0.291 117.630 -0.334
202203 -0.365 121.301 -0.406
202206 -0.327 125.017 -0.353
202209 -0.443 125.227 -0.477
202212 -0.394 125.222 -0.425
202303 -0.044 127.348 -0.047
202306 -0.261 128.729 -0.274
202309 -0.175 129.860 -0.182
202312 -0.187 129.419 -0.195
202403 -0.339 131.776 -0.347
202406 -0.283 132.554 -0.288
202409 -0.174 133.029 -0.176
202412 -0.159 133.157 -0.161
202503 -0.178 134.927 -0.178

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


aTyr Pharma  (NAS:ATYR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


aTyr Pharma Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


aTyr Pharma Business Description

Industry
Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Executives
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jill Marie Broadfoot officer: Chief Financial Officer 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Nancy Krueger officer: See Remarks C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Paul Schimmel director 88 SIDNEY ST, CAMBRIDGE MA 02139
Sanjay Shukla officer: Chief Medical Officer C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Sara Zaknoen director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
John K Clarke director C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542
Svetlana Lucas director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John Mendlein director, officer: CEO and Executive Chairman
Ecor1 Capital Fund Qualified, L.p. 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ashraf Amanullah officer: Vice President, Manufacturing C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John T Blake officer: Vice President, Finance C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
David John King officer: See Remarks 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121